Craft

Pfizer

Stock Price

$28.5

2024-10-29

Market Capitalization

$163.9 B

2024-08-26

Revenue

$58.5 B

FY, 2023

Pfizer Summary

Company Summary

Overview
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. It operates through two business segments: Biopharma and PC1. The Biopharma segment offers medicines, vaccines, and biosimilars for the treatment of cardiovascular and metabolic diseases, oncology diseases, pneumococcal disease, meningococcal disease and tick-borne encephalitis, chronic immune and inflammatory diseases, as well as rare diseases, including amyloidosis, hemophilia, and endocrine diseases. The PC1 segment is a contract development and manufacturing organization and a supplier of specialty active pharmaceutical ingredients.
Type
Public
Status
Active
Founded
1849
HQ
New York, NY, US | view all locations
Website
https://www.pfizer.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Albert Bourla

    Albert Bourla, Chairman and Chief Executive Officer

  • Dave Denton

    Dave Denton, Chief Financial Officer and Executive Vice President

  • Mikael Dolsten

    Mikael Dolsten, Chief Scientific Officer, President, Pfizer Research & Development

  • Lidia Fonseca

    Lidia Fonseca, Chief Digital and Technology Officer, Executive Vice President

Operating MetricsView all

Properties

327
9.9%

FY, 2021

Manufacturing Sites

39
9.3%

FY, 2021

Phase I Trials Products

27

FY, 2021

LocationsView all

119 locations detected

  • New York, NY HQ

    United States

    66 Hudson Blvd E

  • Andover, MA

    United States

    1 Burtt Rd

  • Boulder, CO

    United States

    1825, 1865 and 1885 33rd Street

  • Cambridge, MA

    United States

    1 Portland St

  • Chesterfield, MO

    United States

    875 Chesterfield Pkwy W

  • Collegeville, PA

    United States

    500 Arcola Rd

and 113 others

Pfizer Financials

Summary Financials

Revenue (Q3, 2024)
$17.7B
Gross profit (Q3, 2024)
$12.4B
Net income (Q3, 2024)
$4.5B
Cash (Q3, 2024)
$1.1B
Enterprise value
$224.5B

Footer menu